Regeneron Pharmaceuticals Inc

Healthcare · Biotechnology

803.90$ +0.7% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Balance Sheet

Regeneron Pharmaceuticals Inc (REGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 40,559 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet REGN
Line item	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	138	168	157	137	208	495	392	480	473	424	585	936	670	741	1,089	1,324	2,080	2,951	3,872	5,609	6,973	8,764	11,735	14,805	17,163	25,435	29,215	33,080	37,759	40,559
Current Assets	85	100	93	73	134	394	277	320	344	341	470	798	521	426	720	914	1,621	2,252	2,507	3,384	3,914	5,597	7,959	7,689	12,754	14,015	15,884	19,479	18,661	18,022
Cash	35	29	20	24	31	247	80	118	101	185	238	499	248	207	113	484	230	536	649	809	535	813	1,468	1,618	2,194	2,886	3,106	2,730	2,488	3,118
Cash & Short-Term Investments	35	29	20	66	118	385	264	294	296	299	459	766	475	341	249	527	308	694	1,361	1,677	1,039	2,896	4,565	3,214	6,723	5,695	7,742	10,845	9,013	8,605
Receivables	4.3	6.6	5.7	0.6	14	3.0	4.0	16	43	37	7.5	18	35	66	82	103	693	955	1,017	1,468	1,612	1,974	2,243	2,786	4,115	6,037	5,329	5,667	6,212	5,741
Inventory	–	–	–	4.6	1.9	4.0	6.8	9.0	3.2	2.9	–	–	–	–	-15	14	29	70	129	239	399	726	1,151	1,416	1,917	1,951	2,402	2,581	3,087	3,201
Property, Plant & Equipment	–	–	–	–	37	39	77	81	71	61	49	58	88	260	347	368	380	527	974	1,594	2,083	2,359	2,576	2,890	3,222	3,482	3,763	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	-6,845	–	0.0	–	–
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	6.7	916	1,039	1,149	1,257
Total Liabilities	31	30	26	28	26	229	246	342	291	309	368	476	251	344	562	838	835	999	1,330	1,954	2,524	2,620	2,977	3,716	6,138	6,666	6,551	7,107	8,406	9,302
Current Liabilities	12	11	9.4	13	14	22	40	73	34	40	45	284	84	94	109	148	164	299	620	761	1,241	967	1,352	2,097	2,807	3,933	3,141	3,423	3,944	4,368
Short-Term Debt	3.6	1.8	1.1	1.4	0.6	0.4	0.2	14	19	23	21	200	162	–	0.7	1.0	1.4	0.9	350	453	130	469	91	–	1,631	720	720	–	–	38
Accounts Payable	4.4	4.7	5.6	6.6	9.4	15	30	19	19	23	21	8.1	6.3	19	16	28	39	62	100	141	135	178	218	418	476	564	589	607	790	939
Long-Term Debt	–	–	–	–	2.1	200	200	200	200	200	200	–	–	109	159	275	297	320	147	363	352	703	–	–	1,979	1,980	1,981	1,983	1,984	1,986
Shareholders' Equity	107	139	131	110	182	266	146	138	183	114	217	460	419	397	528	486	1,245	1,952	2,542	3,655	4,449	6,144	8,757	11,090	11,025	18,769	22,664	25,973	29,354	31,257
Retained Earnings	-157	-169	-177	-200	-224	-300	-424	-532	-490	-585	-688	-793	-876	-941	-1,046	-1,267	-517	-93	255	853	1,748	2,947	5,254	7,380	10,893	18,968	23,307	27,260	31,673	35,797
Shares Outstanding	24	29	31	31	35	42	44	50	56	56	58	66	79	80	83	91	115	111	113	115	116	116	115	115	115	112	114	114	115	109

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings